Валеология: Здоровье, Болезнь, Выздоровление. 2020; : 203-211
ФАРМАКОЭКОНОМИЧЕСКАЯ ЭФФЕКТИВНОСТЬ ВИДОВ АЛЛЕРГЕН-СПЕЦИФИЧЕСКОЙ ИММУНОТЕРАПИИ ПРИ ПОЛЛИНОЗЕ
Аннотация
В статье приставлены результаты сравнительной экономической эффективности и рассчитаны прямые затраты видов аллерген-специфической иммунотерапии (АСИТ), а также расходы молекулярной аллергодиагностики на основе серологического IgE с традиционными кожными скариффикационными пробами на основе экстрактов.
Список литературы
1. Schoenwetter W. F. et al. Economic impact and quality-of-life burden of allergic rhinitis // Curr Med Res Opin. – 2004. – Vol. 20. – P. 305–317.
2. Soni A. Allergic Rhinitis: Trends in Use and Expenditures, 2000 to 2005: medical Expenditure Panel Survey / Agency for Healthcare Research and Quality. – Rockville, Maryland, 2008. – 204 р.
3. Stempel D. A., Woolf R. The cost of treating allergic rhinitis // Curr Allergy Asthma Rep. – 2002. – Vol. 2. – P. 223-230.
4. LFrølund P. et al. Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life // Allergy. – 2010. – Vol. 65, № 6. - P. 753–757.
5. Powell R. J. et al. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic Rhinoconjunctivitis // Allergy. – 2007. – Vol. 62. – P. 1335-1338.
6. Hellgren J. et al. Allergic rhinitis and the common cold – high cost to society // Allergy. – 2010. - Vol. 65, № 6. - P. 776–783.
7. Салтабаева У. Ш. Сравнительная оценка эффективности видов аллерген-специфической иммунотерапии при поллинозе: дис. … докт. философии: 6D110100 / У. Ш. Салтабаева. - Астана, 2017. – 200 с.
8. Passalacqua G., Baena-Cagnani C. E., Bousquet J. et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language // J Allergy Clin Immunol. - 2013. – Vol. 132, № 1. - P. 93-98.
9. Saltabayeva U. et al. Allergen-specific immunotherapy in patients with pollinosis // II-oji tarptautinės sveikatos mokslų studentų konf.Ir 18-oj tarptautinės mokslinės-praktinės konferencijos». - Klaipėda,2016. - Р. 143.
10. Stringari G., Tripodi S., Caffarelli C., Dondi A. et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever // J Allergy Clin Immunol. – 2014. – Vol. 134. - P. 75-81.
11. Saltabayeva U., Morenko M., Garib V., Rozenson R. Comparative assessment of the effectiveness of the allergenspecific immunotherapy types with pollinosis / The European Academy of Allergy and Clinical Immunology Annual Congress.
12. Saltabayeva U., Morenko M., Garib V., Rozenson R. et al. Superior economic efficacy of allergen molecule-based diagnosis for prescription of immunotherapy in an area with multiple pollen exposure: a real life study // Annual Meeting of the OEGAI. – Innsbruck, 2016. – P. 51.
13. Zuberbier T., Lotvall J., Simoens S., Subramanian S. V. et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA2LEN review // Allergy. – 2014. – Vol. 69. - P. 1275-1279.
14. Borghesan F., Bernardi D., Plebani M. In vivo and in vitro allergy diagnostics: it is time to reappraise the costs // Clin Chem Lab Med. – 2007. – Vol. 45, № 3. - P. 391-395.
15. Ma S., Nie L., Li H., Wang R., Yin J. Component-Resolved Diagnosis of Peanut Allergy and Its Possible Origins of Sensitization in China // Int Arch Allergy Immunol. – 2016. – Vol. 169. – P. 241-248.
16. Melioli G., Bonifazi F. et al. Passalacqua G. et al. The Immuno CAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms // Clin Biochem. – 2011. – Vol. 44, № 12. - P. 1005–1011.
17. Bergmann K. C. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis // J. All. Clin. Immunol. - 2014 – Vol. 133, № 6. - P. 608-1614.
18. Demoly P., Passalacqua G. et al Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose // Clinical and Translational Allergy. – 2015. - Vol. 5 - P. 1-44.
19. Demoly P., Passalacqua G. et al Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose // Clinical and Translational Allergy. – 2015. - Vol. 5 - P. 1-44.
20. Sampson H. A., Albergo R. Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis // J Allergy Clin Immunol. – 1984. – Vol. 74. - P. 26-33.
21. Niederberger V., Hayek B. et al. Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7 // FASEB J. – 1999. – Vol. 13. – P. 843-856.
22. Asero R., Tripodi S., Dondi A., Sfika I. et al: Prevalence and Clinical Relevance of IgE Sensitization to Profilin in Childhood: A Multicenter Study // Int Arch Allergy Immunol. – 2015. – Vol. 168, № 1. - P. 25-31.
23. Sener O. et al. Comparison of skin tests to aeroallergens in Ankara and Seoul // J Investig Allergol Clin Immunol. – 2003. - Vol. 13, № 3. - P. 202-208.
24. Takai T., Yokota T., Yasue M., Nishiyama C. et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy // Nat Biotechnol. – 1997. – Vol. 15. - P. 754-758.
25. Curin M., Swoboda I., Wollmann E., Lupinek C. et al. Microarrayed dog, cat, and horse allergens show weak correlation between allergen-specific IgE and IgG responses // J Allergy Clin Immunol. – 2014. – Vol. 133. - P. 918-921.
26. Grönlund H., Saarne T. et al. The major cat allergen, Fel d 1, in diagnosis and therapy // Int Arch Allergy Immunol. – 2010 – Vol. 151. - P. 265-267.
27. Saltabayeva U., Morenko M., Garib V., Rozenson R. et al. Greater Real-Life Diagnostic Efficacy of Allergen Molecule-Based Diagnosis for Prescription of Immunotherapy in an Area with Multiple Pollen Exposure // International Archives of Allergy and Immunology. - 2017. Vol. 173, № 2 – P. 93–98.
Valeology: Health - Illnes - recovery. 2020; : 203-211
PHARMACOECONOMIC EFFECTIVENESS OF TYPES OF ALLERGEN-SPECIFIC IMMUNOTHERAPY FOR POLLINOSIS
Abstract
The article presents the results of comparative economic efficiency and calculates the direct costs of allergen-specific immunotherapy types, as well as the costs of molecular allergy diagnostics based on serological IgE with traditional skin extract samples based on extracts.
References
1. Schoenwetter W. F. et al. Economic impact and quality-of-life burden of allergic rhinitis // Curr Med Res Opin. – 2004. – Vol. 20. – P. 305–317.
2. Soni A. Allergic Rhinitis: Trends in Use and Expenditures, 2000 to 2005: medical Expenditure Panel Survey / Agency for Healthcare Research and Quality. – Rockville, Maryland, 2008. – 204 r.
3. Stempel D. A., Woolf R. The cost of treating allergic rhinitis // Curr Allergy Asthma Rep. – 2002. – Vol. 2. – P. 223-230.
4. LFrølund P. et al. Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life // Allergy. – 2010. – Vol. 65, № 6. - P. 753–757.
5. Powell R. J. et al. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic Rhinoconjunctivitis // Allergy. – 2007. – Vol. 62. – P. 1335-1338.
6. Hellgren J. et al. Allergic rhinitis and the common cold – high cost to society // Allergy. – 2010. - Vol. 65, № 6. - P. 776–783.
7. Saltabaeva U. Sh. Sravnitel'naya otsenka effektivnosti vidov allergen-spetsificheskoi immunoterapii pri pollinoze: dis. … dokt. filosofii: 6D110100 / U. Sh. Saltabaeva. - Astana, 2017. – 200 s.
8. Passalacqua G., Baena-Cagnani C. E., Bousquet J. et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language // J Allergy Clin Immunol. - 2013. – Vol. 132, № 1. - P. 93-98.
9. Saltabayeva U. et al. Allergen-specific immunotherapy in patients with pollinosis // II-oji tarptautinės sveikatos mokslų studentų konf.Ir 18-oj tarptautinės mokslinės-praktinės konferencijos». - Klaipėda,2016. - R. 143.
10. Stringari G., Tripodi S., Caffarelli C., Dondi A. et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever // J Allergy Clin Immunol. – 2014. – Vol. 134. - P. 75-81.
11. Saltabayeva U., Morenko M., Garib V., Rozenson R. Comparative assessment of the effectiveness of the allergenspecific immunotherapy types with pollinosis / The European Academy of Allergy and Clinical Immunology Annual Congress.
12. Saltabayeva U., Morenko M., Garib V., Rozenson R. et al. Superior economic efficacy of allergen molecule-based diagnosis for prescription of immunotherapy in an area with multiple pollen exposure: a real life study // Annual Meeting of the OEGAI. – Innsbruck, 2016. – P. 51.
13. Zuberbier T., Lotvall J., Simoens S., Subramanian S. V. et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA2LEN review // Allergy. – 2014. – Vol. 69. - P. 1275-1279.
14. Borghesan F., Bernardi D., Plebani M. In vivo and in vitro allergy diagnostics: it is time to reappraise the costs // Clin Chem Lab Med. – 2007. – Vol. 45, № 3. - P. 391-395.
15. Ma S., Nie L., Li H., Wang R., Yin J. Component-Resolved Diagnosis of Peanut Allergy and Its Possible Origins of Sensitization in China // Int Arch Allergy Immunol. – 2016. – Vol. 169. – P. 241-248.
16. Melioli G., Bonifazi F. et al. Passalacqua G. et al. The Immuno CAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms // Clin Biochem. – 2011. – Vol. 44, № 12. - P. 1005–1011.
17. Bergmann K. C. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis // J. All. Clin. Immunol. - 2014 – Vol. 133, № 6. - P. 608-1614.
18. Demoly P., Passalacqua G. et al Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose // Clinical and Translational Allergy. – 2015. - Vol. 5 - P. 1-44.
19. Demoly P., Passalacqua G. et al Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose // Clinical and Translational Allergy. – 2015. - Vol. 5 - P. 1-44.
20. Sampson H. A., Albergo R. Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis // J Allergy Clin Immunol. – 1984. – Vol. 74. - P. 26-33.
21. Niederberger V., Hayek B. et al. Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7 // FASEB J. – 1999. – Vol. 13. – P. 843-856.
22. Asero R., Tripodi S., Dondi A., Sfika I. et al: Prevalence and Clinical Relevance of IgE Sensitization to Profilin in Childhood: A Multicenter Study // Int Arch Allergy Immunol. – 2015. – Vol. 168, № 1. - P. 25-31.
23. Sener O. et al. Comparison of skin tests to aeroallergens in Ankara and Seoul // J Investig Allergol Clin Immunol. – 2003. - Vol. 13, № 3. - P. 202-208.
24. Takai T., Yokota T., Yasue M., Nishiyama C. et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy // Nat Biotechnol. – 1997. – Vol. 15. - P. 754-758.
25. Curin M., Swoboda I., Wollmann E., Lupinek C. et al. Microarrayed dog, cat, and horse allergens show weak correlation between allergen-specific IgE and IgG responses // J Allergy Clin Immunol. – 2014. – Vol. 133. - P. 918-921.
26. Grönlund H., Saarne T. et al. The major cat allergen, Fel d 1, in diagnosis and therapy // Int Arch Allergy Immunol. – 2010 – Vol. 151. - P. 265-267.
27. Saltabayeva U., Morenko M., Garib V., Rozenson R. et al. Greater Real-Life Diagnostic Efficacy of Allergen Molecule-Based Diagnosis for Prescription of Immunotherapy in an Area with Multiple Pollen Exposure // International Archives of Allergy and Immunology. - 2017. Vol. 173, № 2 – P. 93–98.
